FindTrial
Sign In

MGCD0103

DRUG10 trials

Sponsors

Mirati Therapeutics Inc.

Conditions

Acute Myelogenous LeukemiaAcute Myeloid Leukemia (AML)Hodgkin's LymphomaLeukemiaLymphocytic Leukemia, ChronicLymphomaMyelodysplastic SyndromeMyelodysplastic Syndrome (MDS)

Phase 1

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
CompletedNCT00324194
Mirati Therapeutics Inc.Leukemia, Myelodysplastic Syndromes
Start: 2005-02-28End: 2008-08-31Updated: 2015-01-08
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
CompletedNCT00324129
Mirati Therapeutics Inc.Leukemia, Myelodysplastic Syndromes
Start: 2005-02-28End: 2008-12-31Updated: 2015-01-08
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
CompletedNCT00324220
Mirati Therapeutics Inc.Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Start: 2006-01-31End: 2008-11-30Updated: 2015-07-01
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
CompletedNCT00323934
Mirati Therapeutics Inc.Non Hodgkin's Lymphoma, Tumors
Start: 2004-04-30End: 2008-10-31Updated: 2015-01-08
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
CompletedNCT00372437
Mirati Therapeutics Inc.Tumors
Start: 2006-09-30End: 2008-12-31Updated: 2015-07-01

Phase 2

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
CompletedNCT00359086
Mirati Therapeutics Inc.Lymphoma
Start: 2006-08-31End: 2012-01-31Updated: 2015-07-01
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
TerminatedNCT00358982
Mirati Therapeutics Inc.Hodgkin's Lymphoma
Start: 2006-08-31End: 2009-01-31Updated: 2015-07-03
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
TerminatedNCT00374296
Mirati Therapeutics Inc.Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
Start: 2006-09-30End: 2008-09-30Updated: 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
CompletedNCT00431873
Mirati Therapeutics Inc.Lymphocytic Leukemia, Chronic
Start: 2007-01-31End: 2008-11-30Updated: 2015-07-01
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
TerminatedNCT00666497
Mirati Therapeutics Inc.Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Start: 2008-06-30End: 2009-04-30Updated: 2015-05-08

Related Papers

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
2017-12-1331 citations
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
2011-10-25147 citations